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ABSTRACT: Pharmacokinetics in the posterior eye segment
has therapeutic implications due to the importance of retinal
diseases in ophthalmology. In principle, drug binding to the
components of the vitreous, such as proteins, collagen, or
glycosaminoglycans, could prolong ocular drug retention and
modify levels of pharmacologically active free drug in the
posterior eye segment. Since drug binding in the vitreous has
been investigated only sparsely, we studied vitreal drug binding
of 35 clinical small molecule drugs. Isolated homogenized
porcine vitreous and the drugs were placed in a two-
compartment dialysis system that was used to separate the bound and unbound drug. Free drug concentrations and binding
percentages were quantitated using LC-MS/MS. Drug binding levels varied between 21 and 74% in the fresh vitreous and 0 and
64% in the frozen vitreous. The vitreal binding percentages did not correlate with those in plasma. Our data-based
pharmacokinetic simulations suggest that vitreal binding of small molecule drugs has only a modest influence on the AUC of free
drug or drug half-life in the vitreous. Therefore, it is likely that vitreal binding is not a major reason for interindividual variability
in ocular drug responses or drug−drug interactions.
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■ INTRODUCTION
Posterior tissues of the eye are critically important for the
vision. Therefore, drug treatment of the vitreous, retina,
choroid, and optic nerve is important in many conditions
that endanger the eyesight.1 These conditions include, for
example, infections, inflammatory conditions, neo-vasculariza-
tion, cell proliferation, retinal degenerations, and ocular
malignancies. Drug delivery to the posterior segment of the
eye is usually accomplished by intravitreal injections, other local
ocular injections, or systemic delivery. The drug permeability in
blood ocular barriers has a major impact on the drug clearance
from the vitreous to the blood circulation and, therefore, it is
the main determinant of the half-life of intravitreally injected
drugs.2,3 In addition, drug distribution from the plasma to the
tissues is affected by drug permeability across the tissue-blood
barriers and protein binding of the drug in the plasma and
tissues. Accordingly, drug distribution from the blood
circulation to the vitreous in rabbits has been successfully
predicted based on the drug binding to the plasma proteins and
the distribution clearance across the blood ocular barriers.4 The
extent of the drug binding in the vitreous, however, was not
included in this model, and the importance of vitreal binding is
still unclear.
Vitreous is the largest anatomical compartment in the eye
with volumes of 1.5 and 4 mL in rabbits and humans,
respectively.5 The main components of the human vitreous, in
addition to a water content of 98−99.7%, are proteins and
hyaluronic acid.6 In addition to structural collagens, the vitreous
contains nonstructural proteins, mainly albumin. Estimates of
the total protein content in the vitreous vary between 0.5 and 5
mg/mL,7−10 but are generally assumed to be between 0.5 and
1.5 mg/mL.11 Of this amount, 60−70% is albumin.8,10
Intravitreally injected small molecular drugs are often rapidly
cleared from the vitreous at half-lives less than 10 h.3 It is
believed that the large range of clearance values (about 50-fold)
for small molecule drugs is due to the differences in their
permeability across the blood ocular barriers; high permeability
indicating rapid drug elimination from the vitreous. In
principle, these differences could also be due to major
differences in binding to the proteins and other vitreal
components. Protein concentration (<5 mg/mL) and the
number of proteins (≈ 1300) in the vitreous are less than in
plasma (concentration of 60−80 mg/mL; 3000 protein
species),8 but the binding could also occur with other vitreal
components, such as hyaluronic acid, other glycosaminogly-
cans, and collagen. The rate of molecular diffusion in the
vitreous depends on the size and charge of the diffusing
compound; therefore, increased size and binding to vitreal
components may reduce the mobility and increase the half-life
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of the drug.2,11,12 Recently, Fuchs and Igney13 showed that the
half-life of a nanobody in the rabbit vitreous was prolonged 3-
fold when the compound was coinjected with human serum
albumin. However, binding interactions of small molecule drugs
with the vitreous have not been studied. Extensive drug binding
to the macromolecules in the vitreous should prolong the
vitreal elimination half-life, because the clearance of the
proteins from the vitreous is much slower than the elimination
of the small molecule compounds.3
Drug binding to proteins or other components in the
vitreous may be an important factor in ocular pharmacokinetics
and pharmacodynamics. It is expected to increase drug
distribution from the blood circulation to the eye based on
the distribution equilibrium. Ocular elimination of intravitreally
administered drugs depends on their molecular size, with the
half-lives of protein drugs being in the range of 3−10 days.2,11
Binding to proteins and other vitreal macromolecules should
prolong the drug retention and duration of action in the
vitreous. Protein binding might also lead to pharmacokinetic
changes in the diseased eye, when the vitreous composition or
vitreal protein concentration is affected.
The potential importance of the protein binding of small
molecule drugs in the vitreous is still unknown, and the binding
of drugs to the vitreous humor has only been described in two
conference presentations.14,15 Therefore, we carried out a
systematic study to investigate the binding of 35 small molecule
ocular drugs to the isolated porcine vitreous humor. The drugs
were chosen to represent a wide range of physicochemical
parameters, to be able to cover a variety of molecular properties
that could cause vitreal binding. The equilibrium dialysis
method was used in our study because it allows easy separation
of bound and free drug. Since vitreal binding of drugs is so
poorly known, we used the fraction bound at the equilibrium as
the end-point. We show that vitreal binding of small molecular
weight drugs is relatively low and not a significant factor in
ocular pharmacokinetics.
■ EXPERIMENTAL SECTION
Vitreous Humor. Fresh porcine eyes were obtained from a
local slaughterhouse (HKScan, Forssa, Finland). The eyes were
kept in ice during transportation. Extra tissues from the ocular
surfaces were dissected and removed. The eyes were soaked in
ethanol for 20 s and then placed in Dulbecco's phosphate
buffered saline (DPBS) (without MgCl2 and CaCl2, Gibco,
Thermo Fisher Scientific, Waltham, MA, USA). To avoid
contamination from cellular debris and melanin, approximately
1 mL of vitreous humor was collected per one eye with a
syringe through an incision done about 1 cm posterior to the
iris. Thereafter, the vitreous humor was homogenized under ice
and centrifuged at +4 °C for 60 min at 3200 g. The
homogenized vitreous humor was filtered through filters of
0.45 and 0.22 μm. The vitreous was used for the binding
experiments after it was stored at +4 °C overnight (fresh
vitreous) or at −80 °C (frozen vitreous, thawed before the
experiment). The vitreous from different eyes was pooled
together, and the same vitreous isolate was used throughout the
study.
Drugs. In total 35 drugs were used in the study as a cassette
mixture. The mixture was the same as used by Pelkonen et al.16
(Table 1), and the drugs were dissolved at 1 mg/mL in DMSO
or phosphate buffer as presented in their study. Before the
study, the 1 mg/mL drug cassette was diluted to a
concentration of 10 μg/mL with DPBS (pH 7.4, without
MgCl2 and CaCl2, Gibco, Thermo Fisher Scientific). This
concentration was further diluted to 100 ng/mL in the study
setting. In addition to the cassette experiments, three
compounds (indomethacin, prednisolone, and propranolol)
were tested as individual compounds using dilutions similar to
the ones described above.
Binding Study. Rapid equilibrium dialysis (RED) inserts
(#89809, Thermo Fisher Scientific) were used in the binding
experiments. The donor compartment contained 195 μL of
homogenized vitreous (DPBS instead of vitreous in the control
sample) and 5.5 μL of the cassette mixture. The receiver
compartment contained 350 μL of DPBS (pH 7.4). The final
drug concentration in the total volume of the RED insert was
100 ng/mL. The inserts were incubated at +37 °C during the
binding study and shaken at 225 rpm. Samples of 30 μL were
withdrawn from the receiver compartment at 0, 6, 8, and 24 h,
and equivalent volumes of DPBS were placed in the chamber.
The samples were immediately frozen and stored at −80 °C
until analyzed. The experiments were done in triplicates (both
controls and experiments with the vitreous).
Analytical Methods. Concentrations of the compounds
were determined using a LC-MS/MS technique based on a
previously described method.17 A minimum of six concen-
trations of standards were used for the quantitation of each
drug. Ganciclovir D5, atropine D5, atenolol D7, lornoxicam D4,
indomethacin D4, lincomycin D3, fluconazole D4, dexametha-
sone D5, cephalexin D5, and methotrexate D3 were tested as
internal standards, but, in the final results, dexamethasone D5
and cephalexin D5 were left out due to low peak intensity.
Liquid chromatography separations were carried out using
Waters Acquity UPLC instrument (Waters, MA, USA) coupled
with an Agilent Poroshell 120 SB-C18 (2.7 μm, 2.1 × 50 mm)
column (Agilent Technologies, Inc., Wilmington, DE, USA) at
50 °C. The mobile phase consisted of 0.1% of formic acid in
ultrapure water (A) and 100% of LC-MS grade acetonitrile (B).
The gradient elution started with 2% of B at 0−0.5 min,
continued with 2−100% B at 0.5−7 min, 100% B at 7−12 min,
a reduction to 2% B at 12−12.2 min, and then 2% B at 12.2−14
min for equilibration of the column. The flow-rate was 0.3 mL/
min, and the injection volume was 0.5 μL. After each sample
was injected, two wash injections of isopropanol were made to
prevent carry-over.
Mass spectral experiments were carried out using a Xevo
triple quadrupole mass spectrometer (TQ-S) equipped with an
electrospray ionization (ESI) source (Waters). The ESI source
was operated in the positive ionization mode. The optimal
source parameters were as follows: capillary voltage of 3.5 kV,
cone voltage of 2 V, source temperature of 150 °C, and
desolvation temperature of 600 °C. Nitrogen was used as a
desolvation gas (900 L h−1) and a cone gas (150 L h−1). The
Table 1. Cassette of Drugs Used in the Studya
acetazolamide carteolol indomethacin pilocarpine
acyclovir cephalexin ketorolac pindolol
ampicillin ciprofloxacin levocabastine prednisolone
atenolol dexamethasone lincomycin propanolol
atropine diclofenac lornoxicam quinidine
aztreonam dorzolamide methazolamide tetracycline
betaxolol fluconazol methotrexate tizanidine
brinzolamide fluorometholone nadolol voriconazole
bromfenac ganciclovir penicillin G
aThe mixture is the same as in Pelkonen et al.16
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multiple reaction monitoring (MRM) mode was employed for
quantification. The parameters for each compound are listed in
Table S1 as well as the precursor and fragment ions and
internal standards. The resulting data were analyzed with
Waters MassLynx software. Tetracycline was left out of the
result analysis in the frozen vitreous due to a large variation in
the concentration of replicate samples.
Samples from the individually studied compounds (indome-
thacin, prednisolone, and propranolol) were analyzed with
UPLC (Acquity UPLC, Waters, Milford, MA, USA) with UV
detection (Photodiode Array Detector, Waters). The separation
was carried out on a Luna Omega Polar C-18 (1.6 μm, 2.1 × 50
mm) column (Phenomenex, Torrance, CA, USA) at 30 °C.
The injection volume was 10 μL, and the flow rate 500 μL/min.
A gradient mode was used for all of the compounds with a
mobile phase consisting of 15 mM phosphate buffer (A) and
acetonitrile (B) (0 min 70% A/30% B, 2 min 20% A/80% B).
Data Analysis. The level of drug binding was determined
based on the 8-h data (equilibrium had been reached, data not
shown). Binding levels in the setting ( f b,in vitro) were calculated
using eq 1:
= −f C C C( )/b,in vitro DPBS vitr DPBS (1)
where CDPBS is the drug concentration in the receiver
compartment of the control experiment, and Cvitr is the drug
concentration in the receiver compartment of the experiment
with the vitreous humor.
As dilution is known to cause an increase in the unbound
fraction, the dilution caused by the in vitro setting was taken








((1/ 1) 1/u u,in vitro (2)
where D is the dilution factor (i.e., the ratio of dilution, 550 μL
(total insert volume)/195 μL (vitreous in the donor compart-
ment) = 2.82), and f u,in vitro is the unbound fraction in the in
vitro setting ( f u,in vitro = 1 − f b,in vitro).
Simulation Model. Intravitreal pharmacokinetics were
simulated after an intravitreal injection with the binding results
obtained from this study (Undiluted f u). The fraction bound
was assumed to be constant at all of the drug concentrations.
High and low intravitreal clearance values (0.5 and 0.1 mL/h,
respectively) were used for the unbound compound, and the
bound compound was assumed to have a typical vitreal
clearance of a protein (0.01 mL/h). The simulations assumed a
volume of distribution of 4 mL (human vitreal volume). At this
volume, the half-lives of high and low clearance compounds
(without binding) and protein bound compounds are 5.5, 28,
and 280 h, respectively. The dissociation rate of drug from the
binding site was assumed to be 0.1 min−1 (the range from 0.04
min−1 to 0.04 s−119 had a minimal effect on the results). The
simulations were carried out using Stella Professional software
(Isee Systems, Lebanon, NH, USA).
■ RESULTS
Binding to the fresh vitreous ranged from 9 to 50% and to the
frozen vitreous from 0 to 39% in the in vitro conditions of this
study (Figure S1, Supporting Information). The results taking
into account the dilution in the in vitro setting ranged from 21
to 74% in the fresh vitreous (Figure 1) and from 0 to 64% in
the frozen vitreous (Figure S1).
Binding was similar in the frozen and the fresh vitreous
(Figure 1, Figures S1 and S2), suggesting that frozen vitreous
can be used in the binding studies. The only significant
difference was seen in the case of ampicillin (P < 0.046). The
tests with the individual compounds (indomethacin, predniso-
lone, and propranolol) did not show differences in the binding
levels when compared to the results with the drug mixture
(Figure S3).
On the basis of the simulations, binding in the vitreous is
expected to have a modest impact on the vitreal exposure of the
unbound drug (area under the vitreal concentration curve,
AUC) even at the highest binding levels of 64% (frozen
vitreous) and 74% (fresh vitreous) (Table 2). Although the
elimination half-life in the vitreous increased with increased
binding, changes in the AUC of the free drug were small (Table
2).
We compared the results of vitreal binding with drug binding
to plasma proteins (Figure 2). These two factors did not
correlate with each other.
■ DISCUSSION
We showed that drug binding in the vitreous humor is generally
lower than that in the plasma, and the binding levels are not
correlated (Figure 2). This might reflect the lower protein
concentrations in the vitreous. At equilibrium, higher binding in
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the plasma is expected to lead to higher drug levels in the
plasma than in the vitreous. The simulation model showed that
vitreal binding modulates drug exposure (elimination half-life,
AUC) in the vitreous (Table 2), but binding has a relatively
small impact and does not explain the large differences in the
vitreal clearance of small molecules.3 This conclusion is also
supported by the results of a recent study where the prediction
of drug distribution from blood circulation to the vitreous was
successful without taking into account the vitreal binding of the
drugs.4
Even though most drugs showed less binding in the vitreous
than in the plasma, a few drugs had higher (acyclovir and
ampicillin) or similar binding in the vitreous compared to the
plasma (Figure 2). This suggests that they may bind to
components in the vitreous other than the common plasma
proteins, albumin and α-1-acid glycoprotein. Because the
protein content of the vitreous is considerably lower than
that of the plasma (0.5−1.5 vs 60−80 mg/mL, respectively),
the higher or even similar binding in the vitreous compared to
the plasma is most likely caused by binding to vitreal
components other than the proteins. The negatively charged
hyaluronic acid, the most abundant glycosaminoglycan in the
vitreous, is a prominent candidate for a nonprotein binding
component.
Drug binding to plasma proteins is susceptible to drug−drug
interactions, as two drugs may compete for the same binding
site. Displacement of the “victim” drug from albumin or α-1-
acid glycoprotein may lead to increased free drug concentration
and more intense pharmacological effects.22 The relative change
in the unbound drug concentration is seen if the “victim” drug
has high levels of protein binding. For example, if the binding
level is 99%, displacement of 10% increases the unbound
percentage from 1% to 11%, i.e., a 10-fold change in the
unbound concentration. Changes in the unbound drug levels
are insignificant if the protein binding is, for example, only 30%;
displacement of 10% results in a shift from 70 to 73%, i.e.
practically no change in the unbound concentration. Thus,
considering the binding levels (0−74%), competition of several
drugs for binding sites in the vitreous is most likely an
insignificant factor in ocular pharmacology. The lack of
competition in the experiments in this study (Figure S3) is in
line with this conclusion.
Since this study was carried out using vitreous from porcine
eyes, drawing conclusions about drug binding in the human
vitreous should be done cautiously. The porcine vitreous
contains slightly lower levels of protein and hyaluronic acid
than those of the human vitreous, and the hyaluronic acid in
the porcine vitreous has a lower molecular weight.23 Never-
theless, considering that the protein levels in the human
vitreous are low and the predominant nonprotein component
of both human and porcine vitreous is hyaluronic acid,24 it is
likely that the binding levels are also low in human eyes. The
impact of the disease states in human eyes is another
complicating factor that should be considered. Recently, we
thoroughly analyzed the literature of the disease state
pharmacokinetics in the vitreous and concluded that the
impact of disease states on pharmacokinetics in the posterior
eye segment is surprisingly minor.11 This analysis included
various disease state models, in which also protein levels of the
vitreous may have changed. Even the liquefaction of the
vitreous happening mainly due to aging does not considerably
affect the barrier functions of the vitreous for small molecules,
although some differences in diffusion have been seen.11,25,26 In
liquefaction, the vitreous loses its gel-like appearance, and the
ratio of liquid to gel can increase from 1:4 to 1:1.24,26 Even
though the barrier functions are not affected, the binding could
change due to a change in the composition of the structural
collagens and hyaluronic acid. This in turn could affect the
clearance of the drugs. As the binding to the vitreous was low,
the changes in binding due to liquefaction, while possible, are
expected to be small.
In addition to using porcine vitreous instead of human, the
vitreous was homogenized before studying the binding.
Homogenization was carried out to ease the experimental
procedure and ensure the uniform composition of the vitreous
throughout the study. When extracted from the porcine eye,
the vitreous is not a uniform tissue but has structurally different
segments (liquid and gel). It also contains parts of the
surrounding ocular tissues, such as cellular debris and melanin.
These components can interfere with the binding, especially the
melanin, which is known to bind certain drugs extensively.27 To
avoid contamination by other tissues, we isolated the vitreous
by withdrawing it with a syringe from an opening cut
Table 2. Effect of Binding on the AUC (Free Drug) and
Elimination Half-Life in the Vitreous for a Low and Fast
Clearance Druga
low clearance, CL 0.1 mL/h







fast clearance, CL 0.5 mL/h







aThe highest binding percentage in the frozen vitreous was 64% and in
the fresh vitreous 74%.
Figure 2. Comparison of the plasma protein binding20,21 and vitreal
binding (fresh vitreous) of 27 drugs included in the cassette mix. The
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approximately 1 cm posterior to the iris. This approach,
together with the subsequent homogenization and filtration of
the isolate, is efficient in avoiding contamination but can
change the structure of the vitreous, since mainly the soluble
components of the vitreous are present in the final product.
The soluble proteins of the vitreous are not expected to be
affected considerably by the isolation procedure, but the larger
macromolecules, such as the glycosaminoglycans and collagen,
can be eroded or left on the filter or pellet and not included in
the studied isolate. These changes might affect the binding
results of the study, but as some of the studied drugs bound
more than can be expected based on protein binding, it is likely
that other binding components, such as hyaluronic acid, are
present in the vitreous isolate.
The biochemical composition of the vitreous is not uniform
in the eye.6,28 Thus, the drug binding could vary in different
parts of the vitreous. Hyaluronic acid levels are the highest in
the posterior cortex of the vitreous and the lowest in the
anterior vitreous.28,29 Collagen concentration is the lowest in
the central vitreous and increases toward the basal vitreous
(anterior vitreous) and the cortex. Drug binding in the
approximately 100−300-μm thick vitreous cortex28 would be
the most relevant for drug treatment of the posterior tissues of
the eye, such as the retina and choroid. In the cortical vitreous,
the concentrations of both hyaluronic acid and collagen are
higher than in other parts of the vitreous (high collagen also in
the basal vitreous), which may cause higher drug binding than
in the pooled vitreous of this binding study. Whether this has
an effect on drug distribution in the vitreous is more difficult to
study, as isolating only the cortex of the vitreous would be
difficult.
Treating diseases of the posterior segment of the eye is
generally accomplished by intravitreal or other local ocular
injections.1 These can cause high local concentrations of the
drug, and the therapeutic window of ocular drugs needs to be
relatively wide. The vitreal binding range obtained in this study
was narrow, with unbound fractions varying from 26 to 100%.
Thus, for the studied drugs, vitreal binding is not expected to
have much impact on the efficacy of these drugs in ocular
tissues.
Ocular diseases can affect the composition of the vitreous
humor, but these effects are not well-known, and the extent of
these changes may depend on the disease state. Disease states
do not always result in significant changes in the vitreal protein
levels. For example, the impact of diabetic retinopathy on
protein concentrations in the vitreous was relatively minor.7
Comparative literature analyses of intravitreal drug clearance in
healthy rabbits, diseased rabbits, and human patients suggest
that the diseases have a surprisingly small impact on vitreal drug
clearance.5,11 We do not know the impact of different disease
states on the vitreal drug binding, but most likely these effects
are not important, because (1) only a major increase in binding
(up to >90% levels from current low levels) would result in
significant pharmacokinetic impact, and (2) increased protein
levels in the vitreous are associated with increased permeability
of the blood-retina barrier that increases clearance, while
protein binding tends to decrease it.Finally, the studied drugs
represent a wide range of physicochemical properties with
logD7.4 values varying from −5.1 to 4.2 and polar surface area
from 4.1 to 330 Å.16,17 Therefore, it is likely that the variety of
molecules studied here covers most of the vitreal binding range
expected for small molecules, but it is still possible that some
other molecule binds more extensively to the vitreous. Overall,
we can conclude that binding levels of drugs in the vitreous
seem to be relatively low, with most of the drug being in the
free unbound form. The pharmacological importance of vitreal
binding is only modest, far less than the impact of other factors,
such as the permeability in the blood retina barriers.
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